GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is based in Richmond Hill, Canada.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone905-209-2030
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$410,000.00
Profitability
Miscellaneous
Employees16
OptionableNot Optionable
GeneNews (OTCMKTS:GNWSF) Frequently Asked Questions
What is GeneNews' stock symbol?
GeneNews trades on the OTCMKTS under the ticker symbol "GNWSF."
When is GeneNews' next earnings date?
Has GeneNews been receiving favorable news coverage?
News headlines about GNWSF stock have been trending neutral this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GeneNews earned a daily sentiment score of 0.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the near term.
Who are some of GeneNews' key competitors?
Who are GeneNews' key executives?
GeneNews' management team includes the folowing people:
- Mr. James R. Howard-Tripp, Exec. Chairman & CEO
- Ms. Joanna M. Halsey Esq., Gen. Counsel, Chief Compliance Officer & HR Director of IDL
- Prof. Choong-Chin Liew Ph.D., Co-Founder
- Mr. Warren Whitehead, Chief Accountant (Age 67)
- Mr. David Suria, Sr. Scientist
How do I buy shares of GeneNews?
Shares of GNWSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GeneNews' stock price today?
One share of GNWSF stock can currently be purchased for approximately $0.0403.
How big of a company is GeneNews?
GeneNews has a market capitalization of $6.38 million and generates $410,000.00 in revenue each year. GeneNews employs 16 workers across the globe.
What is GeneNews' official website?
How can I contact GeneNews?
GeneNews' mailing address is 70 East Beaver Creek Road Unit 30, Richmond Hill A6, L4B 3B2. The company can be reached via phone at 905-209-2030 or via email at [email protected]
MarketBeat Community Rating for GeneNews (OTCMKTS GNWSF)
MarketBeat's community ratings are surveys of what our community members think about GeneNews and other stocks. Vote "Outperform" if you believe GNWSF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNWSF will underperform the S&P 500 over the long term. You may vote once every thirty days.
